Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.76 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894502 | 0.91 | VDR (0.67) | VDRPPARAFFAR1FFAR4ARG1 | |
| SCHEMBL2854700 | 0.91 | VDR (0.61) | VDRPPARAFFAR1FFAR4ARG1 | |
| SCHEMBL2639763 | 0.91 | VDR (0.67) | VDRPPARAFFAR1FFAR4NPC1 | |
| SCHEMBL4891909 | 0.89 | VDR (0.84) | VDR | |
| SCHEMBL4888522 | 0.89 | VDR (0.59) | VDRPPARAFFAR1FFAR4 | |
| SCHEMBL2855063 | 0.87 | VDR (1.00) | VDR | |
| SCHEMBL15057551 | 0.84 | VDR (0.61) | VDRPPARACYP3A4 | |
| SCHEMBL4883058 | 0.84 | VDR (0.78) | VDR | |
| SCHEMBL4883065 | 0.83 | VDR (0.71) | VDR | |
| SCHEMBL2641441 | 0.80 | VDR (0.84) | VDRPPARAFFAR1FFAR4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092936-A2 | USE OF 5-AMINOLEVULINIC ACID AND ESTERS, IN COMBINATION WITH A VITAMIN D DERIVATIVE OR ANALOG IN PHOTOCHEMOTHERAPY, AND THEIR USES IN TREATING ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-27 | — | — | WO | claimed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | claimed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | claimed |
| WO-2013092936-A2 | USE OF 5-AMINOLEVULINIC ACID AND ESTERS, IN COMBINATION WITH A VITAMIN D DERIVATIVE OR ANALOG IN PHOTOCHEMOTHERAPY, AND THEIR USES IN TREATING ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-27 | — | — | WO | disclosed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885PPARA 204/4885FFAR1 549/4885 |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | CYP24A1, VDR, SOST | VDR 2/4885PPARA 514/4885FFAR1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.